D&D Pharmatech Inc (XKRX:347850) Share Price

Company Profile

Business description
D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.
Contact
4th floor, 24, Pangyo-ro 255beon-gil
Bundang-gu, Gyeonggi-do
Sampyeong-dong, I&C Building
Seongnam-si
KOR
T: +82 3180197771
http://www.ddpharmatech.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
22

Recommended

Current operating conditions are challenging but over the long-term prospects are better.

Johannes Faul | 25 February 2025

Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.

Joseph Taylor | 25 February 2025

Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.

Morningstar | 25 February 2025

Index	Last price	Change	% Change
All Ordinaries	8,477.30	20.70	-0.24%
CAC 40	8,143.92	92.85	1.15%
DAX 40	22,794.11	383.84	1.71%
Dow JONES (US)	43,412.50	208.66	-0.48%
FTSE 100	8,731.46	62.79	0.72%
HKSE	23,787.93	753.91	3.27%
NASDAQ	19,089.08	62.69	0.33%
Nikkei 225	38,142.37	95.42	-0.25%
NZX 50 Index	12,452.46	145.19	1.18%
S&P 500	5,957.19	1.94	0.03%
S&P/ASX 200	8,240.70	11.20	-0.14%
SSE Composite Index	3,380.21	34.17	1.02%